← Back to headlines
Merck Reports Positive Phase 3 Data for RSV Vaccine ENFLONSIA
Merck announced positive results from its phase 3 second-season RSV data for the vaccine ENFLONSIA, indicating continued efficacy.
19 Feb, 10:25 — 19 Feb, 10:25
Merck announced positive results from its phase 3 second-season RSV data for the vaccine ENFLONSIA, indicating continued efficacy.
19 Feb, 10:25 — 19 Feb, 10:25
